VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease

被引:32
作者
Bangale, Y
Karle, S
Planque, S
Zhou, YX
Taguchi, H
Nishiyama, Y
Li, L
Kalaga, R
Paul, S
机构
[1] Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, Houston, TX 77030 USA
[2] Univ Texas, Sch Med, Dept Med, Chem Immunol Res Ctr, Houston, TX 77030 USA
关键词
SLE; neuroimmune regulation; catalytic antibodies;
D O I
10.1096/fj.02-0475com
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purified IgG from Fas-defective C3H/gld mice, lupus patients, and autoimmune thyroiditis patients. No VIPase activity was detected in IgG from control mice and humans. Kinetic analyses of VIPase IgG preparations suggested low-affinity recognition of VIP. Yet the VIPase activity was VIP selective, judged by lack of correlation with other protease activities expressed by the IgG and by noninterference of unrelated peptides in the activity. Recombinant Fv constructs selected from a human lupus phage show library displayed VIPase activity, confirming that the active site is located in the V domains. Inhibition of the VIPase activity by di-isopropylfluorophosphate suggested a serine protease-like mechanism of catalysis. Irreversible binding of a biotinyated phosphonate diester by the IgG and Fv preparations was observed, consistent with the presence of activated nucleophiles similar to those in enzymes capable of covalent catalysis. These observations show that VIP is a target for specific catalytic autoantibodies in autoimmune disease.
引用
收藏
页码:628 / 635
页数:8
相关论文
共 36 条
[1]   New evidence for transmitter role of VIP in the airways: Impaired relaxation by a catalytic antibody [J].
Berisha, HI ;
Bratut, M ;
Bangale, Y ;
Colasurdo, G ;
Paul, S ;
Said, SI .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2002, 15 (02) :121-127
[2]   Development of systemic lupus erythematosus in mice is associated with alteration of neuropeptide concentrations in inflamed kidneys and immunoregulatory organs [J].
Bracci-Laudiero, L ;
Aloe, L ;
Stenfors, C ;
Theodorsson, E ;
Lundeberg, T .
NEUROSCIENCE LETTERS, 1998, 248 (02) :97-100
[3]  
CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392
[4]   Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease [J].
Delgado, M ;
Abad, C ;
Martinez, C ;
Laceta, J ;
Gomariz, RP .
NATURE MEDICINE, 2001, 7 (05) :563-568
[5]   Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of fas ligand in activated T lymphocytes by regulating c-myc, NF-κB, NF-AT, and early growth factors 2/3 [J].
Delgado, M ;
Ganea, D .
JOURNAL OF IMMUNOLOGY, 2001, 166 (02) :1028-1040
[6]  
Dorsam G, 2000, ANN NY ACAD SCI, V921, P79
[7]   Direct morphological evidence of neuroimmunomodulation in colonic mucosa of patients with Crohn's disease [J].
Fehér, E ;
Kovács, A ;
Gallatz, K ;
Fehér, J .
NEUROIMMUNOMODULATION, 1997, 4 (5-6) :250-257
[8]  
Fersht A., 1985, ENZYME STRUCTURE MEC
[9]   Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs [J].
Ganea, D .
ADVANCES IN NEUROIMMUNOLOGY, 1996, 6 (01) :61-74
[10]  
GAO QS, 1994, J BIOL CHEM, V269, P32389